Evidence on the Efficacy of Omega-3 Polyunsaturated Fatty Acids as an Adjunct Therapy for Chronic Obstructive Pulmonary Disease

Main Article Content

Valerie Josephine Dirjayanto

Abstract

Background: As the fourth leading cause of death worldwide, Chronic Obstructive Pulmonary Disease (COPD) places a significant burden on healthcare-related costs. COPD is characterized by airflow impairment, including chronic bronchitis, small airways obstruction, and emphysema. COPD pathophysiology involves inflammation correlated with lung decline, body composition alteration, and decreased quality of life. Since preceding studies have shown its roles in inflammatory processes, omega-3 is proposed as a potential adjunct treatment in slowing down COPD progression.
Aim: To analyse the efficacy of omega-3 as a potential adjunct therapy in COPD management.
Method: A literature review was conducted by retrieving studies published from 2010-2020 through PubMed, EBSCOhost, Cochrane Controlled Register of Trials (CENTRAL), Scopus, Clinical Key, Wiley, and Science Direct that evaluate the effect of omega-3 supplementation in COPD management.
Outcome: The search yielded 12 studies with a total of 6,474 subjects. Outcomes suggested that omega-3 leads to a reduction in inflammation, improved body composition, enhanced exercise capacity, higher quality of life, and lower exacerbation occurrences. Association found for lung function was weak, but this might be due to the study designs. The only potential adverse effect was diarrhoea, but this is insignificant.
Conclusion: To conclude, omega-3 supplementation in COPD management showed promising results, considering its efficacy in slowing down COPD progression, minimal side effects, cost-effectiveness, and feasibility. However, the incorporation of this intervention into management guidelines require more trials with larger samples to establish more substantial evidence and more in-depth understanding of its roles.

Article Details

How to Cite
Dirjayanto, V. J. (2021) “Evidence on the Efficacy of Omega-3 Polyunsaturated Fatty Acids as an Adjunct Therapy for Chronic Obstructive Pulmonary Disease”, Journal of Asian Medical Students’ Association. Kuala Lumpur, Malaysia, 9(1). doi: 10.52629/jamsa.v9i1.238.
Section
Review Articles

References

Agusti A, Celli BR, Chen R, et al. Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals. Fontana: Global Initiative for Chronic Obstructive Lung Disease; 2019.

World Health Organization. World health statistics 2019: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2019.

GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019 May 11;393(10184):1958-72.

Departemen Kesehatan. Riset Kesehatan Dasar (Riskesdas) 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.

Jones PW, Berry HP, Wiklund I, et all. Development and first validation of the COPD assessment test. CAT. Eur Respir J. 2009;34(3):648-54.

Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci. 2017 Jul 1;131(13):1541-58.

Byun MK, Cho EN, Chang J, et al. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017 Feb;12:669-75.

Simopoulos AP. Omega‐3 fatty acids in wild plants, nuts and seeds. Asia Pac J Clin Nutr. 2002 Sept 26;11(s6):S163-73.

Scoditti E, Massaro M, Garbarino S, et al. Role of diet in chronic obstructive pulmonary disease prevention and treatment. Nutr. 2019 Jun 16;11:1357.

Jho DH, Cole SM, Lee EM, et al. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther. 2004 Jun;3(2):98-111.

Bäck M, Hansson GK. Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J. 2019 Feb;33(2):1536-39.

Schwanke RC, Marcon R, Bento AF, et al. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. Eur J Pharmacol. 2016 Aug;785:156-64.

Ishihara T, Yoshida M, Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol. 2019 Aug;31(9):559-67.

Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017 Oct 15;45(5):1105-15.

Annibaldi A, Meier P. Checkpoints in TNF-induced cell death: implications in inflammation and cancer. Trends Mol Med. 2018 Jan 1;24(1):49-65.

Huang AX, Lu LW, Liu WJ, et al. Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. Med science Monit. 2016 Aug 9;22:2800-08.

de Batlle J, Sauleda J, Balcells E, et al. Association between Ω3 and Ω6 fatty acid intakes and serum inflammatory markers in COPD. J Nutr Biochem. 2012 Jul;23(7):817-21.

Calder PC, Laviano A, Lonnqvist F, et al. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):28-40.

Sugawara K, Takahashi H, Kasai C, et al. Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. Respir Med. 2010 Dec 1;104(12):1883-9.

Nakamoto K, Watanabe M, Sada M, et al. Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: A potential mechanism for progression and exacerbation of COPD. Exp Lung Res. 2019 Sep 14;45(8):255-66.

Williams EJ, Baines KJ, Smart JM, et al. Rosuvastatin, lycopene and omega-3 fatty acids: A potential treatment for systemic inflammation in COPD; a pilot study. J Nutr Intermed Metab. 2016 Sep 1;5:86-95.

Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun. 1983 Nov 30;117(1):282-8.

Cassatella MA, Gasperini S, Calzetti F, et al. Regulated production of the interferon-g-inducible protein10 (IP-10) chemokine by human neutrophils. Eur J Immunol. 1997;27(1):111-5.

McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem. 1998 Jul 3;273(27):16968-75.

Rossaint J, Nadler JL, Ley K, et al. Eliminating or blocking 12/15-lipoxygenase reduces neutrophil recruitment in mouse models of acute lung injury. Crit Care. 2012 Sep 13;16(5):R166.

Choi H, Kim T. Polyunsaturated fatty acids, lung function, and health-related quality of life in patients with chronic obstructive pulmonary disease. Yeungnam Univ J Med. 2020 Apr 7.

Fulton AS, Baldock KL, Coates AM, et al. Polyunsaturated fatty acid intake and lung function in a regional Australian population: A cross-sectional study with a nested case-control analysis. J Clin Nutr Metab. 2019 Dec 1;18:100102.

Leng S, Picchi MA, Tesfaigzi Y, et al. Dietary nutrients associated with preservation of lung function in Hispanic and non-Hispanic white smokers from New Mexico. Int J Obstruct Pulmon Dis. 2017 Oct 30;12:3171.

Ng TP, Niti M, Yap KB, et al. Dietary and supplemental antioxidant and anti-inflammatory nutrient intakes and pulmonary function. Public Health Nutr. 2014 Sep;17(9):2081-6.

Ogasawara T, Marui S, Miura E, et al. Effect of eicosapentaenoic acid on prevention of lean body mass depletion in patients with exacerbation of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Clin Nutr ESPEN. 2018 Dec;28:67-73.

Collins PF, Yang IA, Chang YC, et al. Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. J Thorac Dis. 2019 Oct;11(Suppl 17):S2230-7.

Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J. 1994 Oct;7(10):1793-7.

Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1791-7.

Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993 May;147(5):1151-6.

Ferreira IM, Brooks D, White J, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12; 12:CD000998.

van Beers M, Rutten-van Mölken MP, van de Bool C, et al. Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. Clin Nutr. 2020 Feb 1;39(2):405-13.

van de Bool C, Rutten EPA, van Helvoort A, et al. A randomised clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):748-58.

lahmari AD, Kowlessar BS, Patel ARC, et al. Physical activity and exercise capacity in patients with moderate COPD exacerbations. Eur Respir J. 2016 Aug;48(2):340-9.

Da Silva GPF, Morano MT, Cavalcante, et al. Exercise capacity impairment in COPD patients with comorbidities. Rev Port Pneumol. 2015;21(5):233-8.

Vogiatzis I, Zakynthinos G, Andrianopoulos V. Mechanisms of physical activity limitation in chronic lung diseases. Pulm Med. 2012 Dec 12;2012:634761.

Pepin V, Saey D, Laviolette L, et al. Exercise capacity in chronic obstructive pulmonary disease: mechanisms of limitation. COPD. 2007;4(3):195-204.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7.

Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. J Chron Obstr Pulm Dis. 2005;2(1):105-10.

Ställberg B, Nokela M, Ehrs PO, et al. Validation of the clinical COPD Questionnaire (CCQ) in primary care. Health Qual Life Outcomes. 2009 Mar 25;7:26.

Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-54.

van Reenen M, Janssen B, Oppe M, et al. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument. Rotterdam: EuroQol Research Foundation; 2019 Sep.

Stern AF. The hospital anxiety and depression scale. Occup Med. 2014;64(5):393-4.

Lemoine C, Brigham E, Woo H, et al. Relationship between omega-3 and omega-6 fatty acid intake and COPD morbidity. Ann Am Thorac Soc. 2020;17(3):378-81.

van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003 Apr 28;1:13.

Sundh J, Janson C, Lisspers K, et al. Clinical COPD Questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon Dis. 2012 Dec 20;7:833-42.

Jones PW, Forde W. St George's respiratory questionnaire manual. London: St George’s University; 2009 Jun.

Chauvin A, Rupley L, Meyers K, et al. Outcomes in cardiopulmonary physical therapy: chronic respiratory disease questionnaire (CRQ). Cardiopulm Phys Ther J. 2008;19(2):61-7.

Pavord ID, Jones PW, Burgel P, et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11(Spec Iss):21-30.

Wacker ME, Jörres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016 May 10;16(1):70.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Exacerbation of COPD. Am J Respir Crit Care Med. 2018;198:21-2.